Arne Scheu
CEO Valink Therapeutics
Seminars
Thursday 9th July 2026
Fireside Chat: Beyond PD-1xVEGF- What’s Next for Bispecifics, Emerging Modalities & Non-Oncology Applications?
10:00 am
- Which novel targets and multispecific formats, including bispecific ADCs, could reshape the bispecific and TCE landscape over the next decade, in oncology and beyond?
- As companies move past conventional antibody bispecifics, which strategies or modalities show the most promise for sustained clinical impact, particularly in chronic dosing and non-oncology settings?
- What does multi-targeting enable biologically, and when does added complexity translate into real functional or clinical benefit in long-term and non-oncology treatment paradigms?
- Which early clinical or translational lessons are shaping target selection, modality choice, trial design, and dosing strategies for next-generation multispecifics across oncology and non-oncology indications?
Thursday 9th July 2026
Engineering Complexity with Precision: Designing Next-Generation Bispecific ADCs for Solid Tumour Impact
12:00 pm
- Moving beyond binary gating: Fine-tuned molecular engineering of bispecific ADCs novel synergy between targets to achieve precise and effective cancer treatment
- Leveraging modular platforms for generation of complex biologics (including bispecific ADCs) to control geometry, valency, and site-specific conjugation, enabling unbiased hypothesis generation and rapid prototyping of complex drug candidates
- Advancing solid tumour programs while remaining adaptable to emerging indications and modalities
